New Products:

Product Name: Oxiconazole Nitrate – DMF No: 34173 – Date of Submission: 23-Sep-19
Product Name: Antazoline Phosphate USP – DMF No: 34330 – Date of Submission: 1-Jan-20
Product Name: Clopidogrel Bisulfate USP – DMF No: 34334 – Date of Submission: 5-Feb-20

Metrochem API Pvt Ltd – Active Pharmaceutical Ingredients Manufacturer In India – We manufacture APIs, Intermediates & Pellets. We also do our own R&D.

Metrochem is one of the fastest growing manufacturers of Active Pharmaceutical Ingredients (APIs), Pellets (Semi finished Formulations) and Intermediates in India in Multi -Therapeutic segments like Antiulceratives, Antifungals, Antidiabetic, Antidepressants, Antihypertensive, Antithrombotic/Anticoagulant, Antihistaminic, Antiarthritic, Anti-inflammatory, Antibacterial,Antiaginal,Gastroprokinetic, etc.

Metrochem is a customer-driven company with a focus on chemistry and innovation. At Metrochem, we understand our responsibility to deliver high quality pharmaceutical products and we keep pushing ourselves to continuously improve and achieve our vision of providing reliable end to end pharmaceutical support in high growth, high impact therapeutic areas.

We began our journey with a single facility of Active Pharmaceutical Ingredient (API) manufacturing with two products in our pipeline. Quickly, we backward integrated to Intermediates by starting our Intermediate manufacturing facility in 2005. We then forward integrated to semi-finished formulations by starting our pelletization facility in the year 2006. Over the course of years, we started two more Intermediate manufacturing facilities to fulfill our upstream needs. Since our inception, we focused on generating value through vertical integration and continuous improvement of our infrastructure and manpower.

This foresight about the importance of being vertically integrated allowed us to be always one step ahead of the competition. It helped us better control the quality of the ingredients that go into the final product, have better command on the pricing and be extremely efficient in terms of deliveries. We have also focused on hiring the right, qualified teams to oversee the critical safety, production, QA, QC and Regulatory activities. 

Metrochem API is domain expertise in State-of-the-Art-Facilities to develop analytical methods for evaluating quality of Raw Materials, Intermediates and Final Products. It has capabilities of analysing the impurity profiles and identification of degradation products in their active substances with the use of sophisticated instruments such as GC-MS/MS, multi nuclei NMR (external sources), Preparative HPLC, HPLCs with detectors such as UV, RI, PDA, Fluorescence and ELSD, GCs.

Our manufacturing facilities are approved by several international regulatory bodies such as ISO 9001-2015, USFDA, WHO: GMP, Cofepris and Japanese Accredited, inspected by KFDA authorities and awaiting certification and moving towards USFDA, EU GMP, MHRA & TGA in 2019. Adapting quickly to the ever-evolving demands, we have emerged as one of the fastest growing organizations in the pharmaceutical industry across India. To cater our customer’s high-volume requirements, we have dedicated each of our 6 manufacturing facilities to our 3 core product groups – APIs, Pelletization & Intermediates – reinforced by a well-equipped, centralized Research & Development laboratory.

We are one in the domestic anti-ulcerative segment. We make about 6000 tons of API across different therapeutic segments. Our reactor capacities stand at 2500 KL with a range of 0.05KL to 30KL. We have successfully commercialized more than 300 products across APIs and Pellets. We have a talented workforce of more than 2000 people.

At Metrochem, we are all about long-term relationships. We aim to serve mankind through our high-quality products, and we do this by being transparent, ethical, agile and responsive to our customers. These values helped forge strong bonds over the years and will continue to do so in the future. We have business relationships with over 35 countries and work with 500+ customers across the globe.

Our Vision has always been to develop into an organization that provides end-to-end generic pharmaceutical support in high-impact, high-growth therapeutic areas. Every decision we make is viewed through this lens and therefore our product portfolio covers multiple disease areas. 

We are also into Contract Manufacturing, Contract Research and Custom Synthesis.

Building on the vertical integration front, we are moving towards Oncology, Finished Formulations and P2P business.





Upcoming CPhI Events

Close Menu